我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

在糖尿病和糖代谢异常/糖耐量异常患者中辛伐他汀治疗对血循环白细胞计数的影响

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2012年第6期
页码:
746-748
栏目:
临床研究
出版日期:
2012-12-25

文章信息/Info

Title:
Association of circulating leukocyte count with diabetes mellitus and impaired fasting glucose/impaired glucose tolerance regression after simvastatin treatment
作者:
杨 文于晓红常 艳王玉柱张春燕
(北京海军总医院干二科,北京 100048)
Author(s):
YANG Wen YU Xiao-hong CHANG Yan WANG Yu-zhu ZHANG Chun-yan
(Second Department of Geriatrics, Navy General Hospital, Beijing 100048, China)
关键词:
白细胞计数糖尿病辛伐他汀
Keywords:
peripheral blood leukocyte count simvastatin diabetes mellitus
分类号:
R587.1;R972.6
DOI:
-
文献标识码:
A
摘要:
目的:观察应用辛伐他汀是否可以降低糖尿病和糖代谢异常(IFG)/糖耐量异常(IGT)患者血循环中白细胞计数(WBC)。方法: 糖尿病患者(n=57)、IFG/IGT患者(n=42)和对照组(n=44),服用辛伐他汀(20 mg/d) 6个月。3组患者均进行正常的体力活动,分别于治疗前和治疗6月后清晨空腹抽血测定白细胞计数、血浆总胆固醇(TC)和三酰甘油(TG),并统计其服药前后血压变化的情况。结果: 糖尿病患者、IFG/IGT患者治疗后血循环中白细胞计数和中性粒细胞百分比显著减少(P<0.01,P<0.05),TG和TC在糖尿病、IFG/IGT组和正常对照组治疗后均明显降低(P<0.01或P<0.05)。结论: 辛伐他汀可以明显降低糖尿病和IFG/IGT患者血循环中的WBC、中性粒细胞百分比。
Abstract:
AIM:To investigate the effects of simvastatin on the levels of peripheral blood leukocyte count, serum total cholesterol and triglycerides in patients with diabetes mellitus and impaired fasting glucose/impaired glucose tolerance (IFG/IGT). METHODS: Diabetes mellitus patients [n=57, 48 males, average age (74±9) years], IFG/IGT patients [n=42, 35 males, average age (73±6) years] and controls [n=44, 37 males, average age (74±7) years] were subjected to simvastatin treatment (20 mg/day) for 6 months. Patients in all three groups performed normal physical activity and plasma samples were collected after overnight fasting at baseline before and after the 6-month treatment for examination. RESULTS: Simvastatin treatment significantly reduced the peripheral blood leukocyte count and percentage of neutrophils in IFG/IGT and patients with diabetes mellitus (P<0.01, P<0.05). Post-treatment levels of plasma triglycerides were significantly lower than those pre-treatment in patients with diabetes mellitus and IFG/IGT (P<0.01). Post-treatment levels of total plasma cholesterol were significantly lower compared with those pre-treatment in all three groups (P<0.01, P<0.05). CONCLUSION: Simvastatin markedly lowered peripheral blood leukocyte count and plasma triglyceride levels and the percentage of neutrophils in patients with diabetes mellitus and IFG/IGT. Statin-induced inhibition of peripheral blood leukocyte count may play an important role in the pharmacological treatment of cardiovascular diseases.

参考文献/References

[1]Loimaala A,Rontu R,Vuori I,et al.Blood leukocyte count is a risk factor for intima-media thickening and subclinical carotid atherosclerosis in middle-aged men[J].Atherosclerosis, 2006,188(2):363-369.
[2]Vozarova B,Weyer C,Lindsay RS,et al.High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes[J].Diabetes,2002,51(2):455-461.
[3]Imano H,Sato S,Kitamura A,et al.Leukocyte count is an independent predictor for risk of acute myocardial infarction in middle-aged Japanese men[J].Atherosclerosis,2007,195(1):147-152.
[4]Chen W,Srinivasan SR,Xu J,et al.Black-white divergence in the relation of white blood cell count to metabolic syndrome in preadolescents, adolescents, and young adults: the Bogalusa Heart Study[J].Diabetes Care,2010,33(11):2474-2476.
[5]Ascer E,Bertolami MC,Venturinelli ML,et al.Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients[J].Atherosclerosis,2004,177(1):161-166.
[6]Yoon SS,Dillon CF,Carroll M,et al.Effects of statins on serum inflammatory markers: The U.S. national health and nutrition examination survey 1999-2004[J].J Atheroscler Thromb,2010,17(11):1176-1182.
[7]Rezaie-Majd A,Maca T,Bucek R,et al.Simvastatin reduces expression of cytokines interleukin-6,interleukin-8,and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients[J].Arterioscler Thromb Vasc Biol,2002,22(7):1194-1199.
[8]Proost P,Wuyts A,Van Damme J.The role of chemokines in inflammation[J].Int J Clin Lab Res, 1996,26(4):211-223.
[9]Davignon J,Laaksonen R.Low-density lipoprotein-independent effects of statins[J].Curr Opin Lipidol,1999,10(6):543-559.
[10]Tedgui A,Mallat Z.Anti-inflammatory mechanisms in the vascular wall[J].Circ Res,2001,88(9):877-887.
[11]De Martin R, Hoeth M,Hofer-Warbinek R,et al.The transcription factor NF-κB and the regulation of vascular cell function[J].Arterioscler Thromb Vasc Biol,2000,20(11):E83-E 88.
[12]Alipour A,van Oostrom AJ,Izraeljan A,et al.Leukocyte activation by triglyceride-rich lipoproteins[J].Arterioscler Thromb Vasc Biol,2008,28(4):792-797.

备注/Memo

备注/Memo:
收稿日期:2012-04-01.作者简介:杨文,副主任医师,硕士 Email:yangwen666123@sohu.com
更新日期/Last Update: 2012-12-30